Hiv Vaccine Market By Clinical Trial ( Phase I, Phase Ii And Phase Iii) - Global Industry Analysis And Forecast To 2023

Published On : July 2018 Pages : 116 Category: Biotechnology Report Code : HC071071

Industry Outlook and Trend Analysis

The HIV Vaccines Market was worth USD 1.23 billion in 2014 and is expected to reach approximately USD 1.95 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 5.30% during the forecast period. Antibodies are among the most ground-breaking and savvy illness anticipation instruments. An antibody that could keep the HIV contamination or stop the advancement of the infection would significantly bolster in the battle against the AIDS ailment. Immunizations have been pivotal in overall smallpox disposal endeavours, have almost dispensed with polio and have definitely decreased the frequency of irresistible infections like measles and pertussis in the US. In any case, the inquiry is emerging that whether HIV antibody ought to be created for a solitary strain or it ought to be intended for differed strain structures. The entire point is to give the better drug to the annihilation of the infection using necessary means.

Drivers & Restrains

The worldwide market for HIV antibody is one of the quickest developing markets. In spite of the fact that there is no business HIV immunization accessible in the market; there is tremendous financing for the exploration and advancement of HIV antibody. The development of the market is probably going to drive by rising Research and development subsidizing for HIV antibody, rising predominance of HIV because of prostitution, expanding awareness because of HIV counteractive action programs, developing number of new contestants in the market.

Regional Outlook and Trend Analysis

North America is expected to witness considerable growth over the forecast period. The substantial size of the market can be credited to higher selection of different HIV immunization preliminaries combined with nearness of technological advancement. Europe is the second-biggest market for HIV antibody which is expected to take up good growth. Asia-Pacific HIV market is required to develop with a relentless pace.

Competitive Insights

The leading players in the market are Janssen Global Services, Llc , Argos Therapeutics, Inc., Paxvax Corporation, Geovax, Glaxosmithkline Plc and others. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

The HIV Vaccines Market is segmented as follows-

By Clinical Trials:

  • Phase I
  • Phase II
  • Phase III

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • South Africa
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Some of the key questions answered by the report are:

  • What was the market size in 2014 and forecast from 2015 to 2023?
  • What will be the industry market growth from 2015 to 2023?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         HIV Vaccine  Market, By Clinical Trial, Estimates and Forecast, 2014-2023 ($Million)

·         PHASE I

·         PHASE II

·         PHASE III

·         HIV Vaccine  Market, By Region, Estimates and Forecast, 2014-2023 ($Million)

·         North America

§  North America HIV Vaccine  Market, By Country

o    U.S. HIV Vaccine  Market

o    Canada HIV Vaccine  Market

o    Mexico HIV Vaccine  Market

·         Europe

§  Europe HIV Vaccine  Market, By Country

o    Germany HIV Vaccine  Market

o    UK HIV Vaccine  Market

o    France HIV Vaccine  Market

o    Russia HIV Vaccine  Market

o    Italy HIV Vaccine  Market

o    Rest of Europe HIV Vaccine  Market

·         Asia-Pacific

§  Asia-Pacific HIV Vaccine  Market, By Country

o    China HIV Vaccine  Market

o    Japan HIV Vaccine  Market

o    South Korea HIV Vaccine  Market

o    India HIV Vaccine  Market

o    Southeast Asia HIV Vaccine  Market

o    Rest of Asia-Pacific HIV Vaccine  Market

·         South America

§  South America HIV Vaccine  Market

o    Brazil HIV Vaccine  Market

o    Argentina HIV Vaccine  Market

o    Columbia HIV Vaccine  Market

o    South Africa HIV Vaccine  Market

o    Rest of South America HIV Vaccine  Market

·         Middle East and Africa

§  Middle East and Africa HIV Vaccine  Market

o    Saudi Arabia HIV Vaccine  Market

o    UAE HIV Vaccine  Market

o    Egypt HIV Vaccine  Market

o    Nigeria HIV Vaccine  Market

o    South Africa HIV Vaccine  Market

o    Rest of MEA HIV Vaccine  Market

Table of Contents

1.       Introduction

1.1.       Report Description

1.2.       Research Methodology

1.2.1.  Secondary Research

1.2.2.  Primary Research

2.       Executive Summary

2.1.       Key Highlights

3.       Market Overview

3.1.       Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.       Market Dynamics

3.2.1.  Drivers

3.2.1.1.    Increasing awareness due to HIV prevention programs

3.2.1.2.    Rising Research U Development funding for HIV Vaccine Market

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.       North America (United States, Canada and Mexico)

4.1.1.  United States Market States and Outlook (2014-2023)

4.1.2.  Canada Market States and Outlook (2014-2023)

4.1.3.  Mexico Market States and Outlook (2014-2023)

4.2.       Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market States and Outlook (2014-2023)

4.2.2.  France Market States and Outlook (2014-2023)

4.2.3.  UK Market States and Outlook (2014-2023)

4.2.4.  Russia Market States and Outlook (2014-2023)

4.2.5.  Italy Market States and Outlook (2014-2023)

4.2.6.  Rest of Europe Market States and Outlook (2014-2023)

4.3.       Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market States and Outlook (2014-2023)

4.3.2.  Japan Market States and Outlook (2014-2023)

4.3.3.  Korea Market States and Outlook (2014-2023)

4.3.4.  India Market States and Outlook (2014-2023)

4.3.5.  Rest of Asia-Pacific Market States and Outlook (2014-2023)

4.4.       South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market States and Outlook (2014-2023)

4.4.2.  Argentina Market States and Outlook (2014-2023)

4.4.3.  Columbia Market States and Outlook (2014-2023)

4.4.4.  Rest of South America Market States and Outlook (2014-2023)

4.5.       Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market States and Outlook (2014-2023)

4.5.2.  UAE Market States and Outlook (2014-2023)

4.5.3.  Egypt Market States and Outlook (2014-2023)

4.5.4.  Nigeria Market States and Outlook (2014-2023)

4.5.5.  South Africa Market States and Outlook (2014-2023)

4.5.6.  Rest of MEA Market States and Outlook (2014-2023)

5.       HIV Vaccine Market, By Clinical Trial

5.1.       Introduction

5.2.       Global HIV Vaccine Market Revenue and Market Share by Clinical Trial (2014-2018)

5.2.1.  Global HIV Vaccine Market Revenue and Revenue Share by Clinical Trial (2014-2018)S

5.3.       PHASE I

5.3.1.  Global PHASE I Revenue and Growth Rate (2014-2018)

5.4.       PHASE II

5.4.1.  Global PHASE II Revenue and Growth Rate (2014-2018)

5.5.       PHASE III

5.5.1.  Global PHASE III Revenue and Growth Rate (2014-2018)

6.       HIV Vaccine Market, By Region

6.1.       Introduction

6.2.       Global HIV Vaccine Market Revenue and Market Share by Regions

6.2.1.  Global HIV Vaccine Market Revenue by Regions (2014-2018)

6.3.       North America HIV Vaccine Market by Countries

6.3.1.  North America HIV Vaccine Market Revenue and Growth Rate (2014-2018)

6.3.2.  North America HIV Vaccine Market Revenue by Countries (2014-2018)

6.3.3.  North America HIV Vaccine Market Revenue (Million USD) by Countries (2014-2018)

6.3.4.  U.S.

6.3.4.1.    United States HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.3.5.  Canada

6.3.5.1.    Canada HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.3.6.  Mexico

6.3.6.1.    Mexico HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.4.       Europe HIV Vaccine Market by Countries

6.4.1.  Europe HIV Vaccine Market Revenue and Growth Rate (2014-2018)

6.4.2.  Europe HIV Vaccine Market Revenue by Countries (2014-2018)

6.4.3.  Europe HIV Vaccine Market Revenue (Million USD) by Countries (2014-2018)

6.4.4.  Germany

6.4.4.1.    Germany HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.4.5.  UK

6.4.5.1.    UK HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.4.6.  France

6.4.6.1.    France HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.4.7.  Russia

6.4.7.1.    Russia HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.4.8.  Italy

6.4.8.1.    Italy HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.4.9.  Rest of Europe

6.4.9.1.    Rest of Europe HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.5.       Asia-Pacific

6.5.1.  Asia-Pacific HIV Vaccine Market Revenue and Growth Rate (2014-2018)

6.5.2.  Asia-Pacific HIV Vaccine Market Revenue by Countries (2014-2018)

6.5.3.  Asia-Pacific HIV Vaccine Market Revenue (Million USD) by Countries (2014-2018)

6.5.4.  China

6.5.4.1.    China HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.5.5.  Japan

6.5.5.1.    Japan HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.5.6.  Korea

6.5.6.1.    Korea HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.5.7.  India

6.5.7.1.    India HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.5.8.  Southeast Asia

6.5.8.1.    Southeast Asia HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.5.9.  Rest of Asia-Pacific

6.5.9.1.    Rest of Asia-Pacific HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.6.       South America

6.6.1.  South America HIV Vaccine Market Revenue and Growth Rate (2014-2018)

6.6.2.  South America HIV Vaccine Market Revenue by Countries (2014-2018)

6.6.3.  South America HIV Vaccine Market Revenue (Million USD) by Countries (2014-2018)

6.6.4.  Brazil

6.6.4.1.    Brazil HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.6.5.  Argentina

6.6.5.1.    Argentina HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.6.6.  Columbia

6.6.6.1.    Columbia HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.6.7.  Rest of South America

6.6.7.1.    Rest of South America HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.7.       Middle East and Africa

6.7.1.  Middle East and Africa HIV Vaccine Market Revenue and Growth Rate (2014-2018)

6.7.2.  Middle East and Africa HIV Vaccine Market Revenue by Countries (2014-2018)

6.7.3.  Middle East and Africa HIV Vaccine Market Revenue (Million USD) by Countries (2014-2018)

6.7.4.  Saudi Arabia

6.7.4.1.    Saudi Arabia HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.7.5.  United Arab Emirates

6.7.5.1.    United Arab Emirates HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.7.6.  Egypt

6.7.6.1.    Egypt HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.7.7.  Nigeria

6.7.7.1.    Nigeria HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.7.8.  South Africa

6.7.8.1.    South Africa HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.    Rest of Middle East and Africa HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2014-2018)

7.       Company Profiles

7.1.       GENECURE LLC

7.1.1.  Business Overview

7.1.2.  Product Portfolio

7.1.3.  Strategic Developments

7.1.4.  Revenue and Market Share

7.2.       BIONOR PHARMA ASA

7.2.1.  Business Overview

7.2.2.  Product Portfolio

7.2.3.  Strategic Developments

7.2.4.  Revenue and Market Share

7.3.       ARGOS THERAPEUTICS, INC.

7.3.1.  Business Overview

7.3.2.  Product Portfolio

7.3.3.  Strategic Developments

7.3.4.  Revenue and Market Share

7.4.       JANSSEN GLOBAL SERVICES, LLC

7.4.1.  Business Overview

7.4.2.  Product Portfolio

7.4.3.  Strategic Developments

7.4.4.  Revenue and Market Share

7.5.       GEOVAX

7.5.1.  Business Overview

7.5.2.  Product Portfolio

7.5.3.  Strategic Developments

7.5.4.  Revenue and Market Share

7.6.       PAXVAX CORPORATION

7.6.1.  Business Overview

7.6.2.  Product Portfolio

7.6.3.  Strategic Developments

7.6.4.  Revenue and Market Share

7.7.       GENVEC, INC.

7.7.1.  Business Overview

7.7.2.  Product Portfolio

7.7.3.  Strategic Developments

7.7.4.  Revenue and Market Share

7.8.       GLAXOSMITHKLINE PLC

7.8.1.  Business Overview

7.8.2.  Product Portfolio

7.8.3.  Strategic Developments

7.8.4.  Revenue and Market Share

7.9.       INOVIO PHARMACEUTICALS, INC.

7.9.1.  Business Overview

7.9.2.  Product Portfolio

7.9.3.  Strategic Developments

7.9.4.  Revenue and Market Share

7.10.    SANOFI

7.10.1.      Business Overview

7.10.2.      Product Portfolio

7.10.3.      Strategic Developments

7.10.4.      Revenue and Market Share

8.       Global HIV Vaccine Market Competition, by Manufacturer

8.1.       Global HIV Vaccine Market Revenue and Market Share by Manufacturer (2016-2017)

8.2.       Global HIV Vaccine Market Price by Region (2016-2017)

8.3.       Top 5 HIV Vaccine Market Manufacturer Market Share

8.4.       Market Competition Trend

9.       HIV Vaccine Market Forecast (2018-2023)

9.1.       Global HIV Vaccine Market Revenue (Millions USD) and Growth Rate (2018-2023)

9.2.       HIV Vaccine Market Forecast by Regions (2018-2023)

9.2.1.  North America HIV Vaccine Market Forecast (2018-2023)

9.2.1.1.    United States HIV Vaccine Market Forecast (2018-2023)

9.2.1.2.    Canada HIV Vaccine Market Forecast (2018-2023)

9.2.1.3.    Mexico HIV Vaccine Market Forecast (2018-2023)

9.2.2.  Europe HIV Vaccine Market Forecast (2018-2023)

9.2.2.1.    Germany HIV Vaccine Market Forecast (2018-2023)

9.2.2.2.    United Kingdom HIV Vaccine Market Forecast (2018-2023)

9.2.2.3.    France HIV Vaccine Market Forecast (2018-2023)

9.2.2.4.    Russia HIV Vaccine Market Forecast (2018-2023)

9.2.2.5.    Italy HIV Vaccine Market Forecast (2018-2023)

9.2.2.6.    Rest of the Europe HIV Vaccine Market Forecast (2018-2023)

9.2.3.  Asia-Pacific HIV Vaccine Market Forecast (2018-2023)

9.2.3.1.    China HIV Vaccine Market Forecast (2018-2023)

9.2.3.2.    Japan HIV Vaccine Market Forecast (2018-2023)

9.2.3.3.    Korea HIV Vaccine Market Forecast (2018-2023)

9.2.3.4.    India HIV Vaccine Market Forecast (2018-2023)

9.2.3.5.    Southeast Asia HIV Vaccine Market Forecast (2018-2023)

9.2.3.6.    Rest of Asia-Pacific HIV Vaccine Market Forecast (2018-2023)

9.2.4.  South America HIV Vaccine Market Forecast (2018-2023)

9.2.4.1.    Brazil HIV Vaccine Market Forecast (2018-2023)

9.2.4.2.    Argentina HIV Vaccine Market Forecast (2018-2023)

9.2.4.3.    Columbia HIV Vaccine Market Forecast (2018-2023)

9.2.4.4.    Rest of South America HIV Vaccine Market Forecast (2018-2023)

9.2.5.  Middle East and Africa HIV Vaccine Market Forecast (2018-2023)

9.2.5.1.    Saudi Arabia HIV Vaccine Market Forecast (2018-2023)

9.2.5.2.    UAE HIV Vaccine Market Forecast (2018-2023)

9.2.5.3.    Egypt HIV Vaccine Market Forecast (2018-2023)

9.2.5.4.    Nigeria HIV Vaccine Market Forecast (2018-2023)

9.2.5.5.    South Africa HIV Vaccine Market Forecast (2018-2023)

9.2.5.6.    Rest of MEA HIV Vaccine Market Forecast (2018-2023)

9.3.       HIV Vaccine Market Forecast by Clinical Trial (2018-2023)

9.3.1.  Global HIV Vaccine Market Revenue Forecast by Clinical Trial (2018-2023)

9.3.2.  Global HIV Vaccine Market Revenue Market Share Forecast by Clinical Trial (2018-2023)


List of Tables

*You can glance through the list of Tables and Figures when you view the sample copy of HIV Vaccine Market.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*